AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II


Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Upside 206%
Price (€) 3.78
Market Cap (€M) 138
Perf. 1W: -4.55%
Perf. 1M: -5.50%
Perf. 3M: -3.57%
Perf Ytd: 14.7%
10 day relative perf. to stoxx600: -4.24%
20 day relative perf. to stoxx600: -6.71%

Success of the capital increase


Crossject has announced that the c.€4m capital increase had been subscribed with, among others, c. 1,656k shares by Gemmes Venture (the group’s historic shareholder, which now controls 30.6% of the share capital) out of a total of c.3.4m new shares. The new number of shares stands at 13.6m and new shares will be listed as from 28 December.


The capital increase was already included in our numbers. We will only adjust them to account for the conversion of warrants since September that led to a high number of shares pre capital increase.


04 Feb 19 Financing issue
Some extra non-dilutive financing

24 Dec 18 EPS change
Adjustment in the number of shares

28 Nov 18 Financing issue
A €3.9m capital increase

23 Oct 18 Other news/comments
Bond conversion

27 Sep 18 Earnings/sales releases
H1 18: insignificant; some more time needed to ...

05 Sep 18 Target Change
On its way to reaching the market